AM-Pharma Enters into an Exclusive License Agreement with Kyowa Kirin to Commercialize Ilofotase Alfa in Japan
Shots:
- AM-Pharma to receive $23.6M up front- $35.4M in milestones before regulatory submission and ~$230.4M upon submission- NHI price listing & sales milestone along with royalties on sales and a drug supply fee
- Kyowa Kirin to get the exclusive right to develop and commercialize ilofotase alfa in Japan. Ilofotase alfa is currently being evaluated in a P-III REVIVAL study in 1600 patients with SA-AKI
- AM-Pharma is responsible for the completion of the P-III REVIVAL study & P-I PK- safety- and tolerability study in Japan. Kyowa Kirin will lead the regulatory approval process and commercialization of ilofotase alfa in Japan
| Ref: Business wire | Image: Kyowa Kirin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com